首页> 美国卫生研究院文献>Frontiers in Medicine >Impact of an 18F-FDG PET/CT Radiotracer Injection Infiltration on Patient Management—A Case Report
【2h】

Impact of an 18F-FDG PET/CT Radiotracer Injection Infiltration on Patient Management—A Case Report

机译:18F-FDG PET / CT放射性示踪剂注入渗透对患者管理的影响-病例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Major management decisions in patients with solid tumors and lymphomas are often based on 18F-fluorodeoxyglucose (18F-FDG) PET/CT. The misadministration of 18F-FDG outside the systemic circulation can have an adverse impact on this test's sensitivity () and is not uncommon (–). This report describes how an 18F-FDG misadministration led to a repeat PET/CT study, resulting in the visualization of distant metastases that changed the original treatment plan. The findings suggest that routine injection monitoring is indicated whenever sensitivity is critical, and support claims that infiltrations can confound interpretation of semi-quantitative PET outcome measures in patients who are followed longitudinally ().
机译:实体瘤和淋巴瘤患者的主要治疗决策通常基于18F-氟脱氧葡萄糖(18F-FDG)PET / CT。体循环以外使用18F-FDG可能会对该测试的敏感性()产生不利影响,而且这种情况并不罕见(–)。该报告描述了18F-FDG误用药如何导致重复的PET / CT研究,从而可视化了远处转移,从而改变了原始治疗计划。研究结果表明,只要敏感度至关重要,就应进行常规注射监测,并支持浸润可以混淆纵向随访患者的半定量PET结局指标的解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号